# Determine the Effect of AZD3161,Injected Intradermally, on Quantitative Sensory Testing Variables in Normal and Ultraviolet-C (UVC) Exposed Skin in Healthy Volunteers

> **NCT01240148** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 26 (actual)

## Conditions studied

- Peripheral Neuropathic Pain
- Nociceptive Pain

## Interventions

- **DRUG:** AZD3161
- **DRUG:** Lidocaine
- **DRUG:** AZD3161 Placebo

## Key facts

- **NCT ID:** NCT01240148
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2011-03
- **Final completion:** 2011-03
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2011-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01240148

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01240148, "Determine the Effect of AZD3161,Injected Intradermally, on Quantitative Sensory Testing Variables in Normal and Ultraviolet-C (UVC) Exposed Skin in Healthy Volunteers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01240148. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*